Literature DB >> 21601333

Relapsing and recurrent peritoneal dialysis-associated peritonitis: a multicenter registry study.

Michael Burke1, Carmel M Hawley, Sunil V Badve, Stephen P McDonald, Fiona G Brown, Neil Boudville, Kathryn J Wiggins, Kym M Bannister, David W Johnson.   

Abstract

BACKGROUND: The causes, predictors, treatment, and outcomes of relapsed and recurrent peritoneal dialysis (PD)-associated peritonitis are poorly understood. STUDY
DESIGN: Observational cohort study using Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry data. SETTING & PARTICIPANTS: All Australian PD patients between October 1, 2003, and December 31, 2007, with first episodes of peritonitis. PREDICTORS: Demographic, clinical, and facility variables and type of peritonitis; relapse (same organism or culture-negative episode occurring within 4 weeks of completion of therapy of a prior episode or 5 weeks if vancomycin used); recurrence (different organism occurring within 4 weeks of completion of therapy of a prior episode or 5 weeks if vancomycin used); control (first peritonitis episode without relapse or recurrence). OUTCOMES & MEASUREMENTS: Hospitalization, catheter removal, hemodialysis therapy transfer, death.
RESULTS: Of 6,024 PD patients studied, first episodes of relapsed, recurrent, and control peritonitis occurred in 356, 165, and 2,021 patients, respectively. Coagulase-negative staphylococci and Staphylococcus aureus accounted for 48% of relapsing peritonitis (adjusted OR, 1.26 [95% CI, 0.94-1.70] and 1.54 [95% CI, 1.08-2.19], respectively), but were much less likely to be isolated in recurrent peritonitis. Recurrent peritonitis was associated more frequently with fungi (13%; OR, 2.16; 95% CI, 1.12-4.17). The empirical antimicrobial approaches to relapsing and recurrent peritonitis were similar and their subsequent clinical outcomes were comparable. Compared with uncomplicated peritonitis, relapsed and recurrent peritonitis were associated with higher rates of catheter removal (22% vs 30% vs 37%, respectively; P < 0.001) and permanent hemodialysis therapy transfer (20% vs 25% vs 32%; P < 0.001), but similar rates of hospitalization (73% vs 70% vs 70%) and death (2.8% vs 2.0% vs 1.2%). LIMITATIONS: Limited covariate adjustment. Residual confounding and coding bias could not be excluded.
CONCLUSIONS: Relapsed and recurrent peritonitis are caused by different spectra of micro-organisms, but are not readily clinically distinguishable at presentation. Empirical treatment with broad-spectrum antibiotics and subsequent adjustment according to antimicrobial susceptibilities results in similar clinical outcomes, albeit with appreciably higher rates of catheter removal and hemodialysis therapy transfer than for uncomplicated peritonitis. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21601333     DOI: 10.1053/j.ajkd.2011.03.022

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  21 in total

1.  Identification of Specific Components of the Eicosanoid Biosynthetic and Signaling Pathway Involved in Pathological Inflammation during Intra-abdominal Infection with Candida albicans and Staphylococcus aureus.

Authors:  Mélanie A C Ikeh; Paul L Fidel; Mairi C Noverr
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

2.  The role of monitoring gentamicin levels in patients with gram-negative peritoneal dialysis-associated peritonitis.

Authors:  Wen Tang; Yeoungjee Cho; Carmel M Hawley; Sunil V Badve; David W Johnson
Journal:  Perit Dial Int       Date:  2014-01-02       Impact factor: 1.756

3.  Recent peritonitis associates with mortality among patients treated with peritoneal dialysis.

Authors:  Neil Boudville; Anna Kemp; Philip Clayton; Wai Lim; Sunil V Badve; Carmel M Hawley; Stephen P McDonald; Kathryn J Wiggins; Kym M Bannister; Fiona G Brown; David W Johnson
Journal:  J Am Soc Nephrol       Date:  2012-05-24       Impact factor: 10.121

4.  American Society of Nephrology Quiz and Questionnaire 2013: RRT.

Authors:  Rajnish Mehrotra; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 8.237

Review 5.  Continuous Quality Improvement Initiatives to Sustainably Reduce Peritoneal Dialysis-Related Infections in Australia and New Zealand.

Authors:  Melissa Nataatmadja; Yeoungjee Cho; David W Johnson
Journal:  Perit Dial Int       Date:  2016-09-10       Impact factor: 1.756

6.  Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity.

Authors:  Brian M Peters; Mairi C Noverr
Journal:  Infect Immun       Date:  2013-04-01       Impact factor: 3.441

Review 7.  Difficult peritonitis cases in children undergoing chronic peritoneal dialysis: relapsing, repeat, recurrent and zoonotic episodes.

Authors:  Sevcan A Bakkaloglu; Bradley A Warady
Journal:  Pediatr Nephrol       Date:  2014-09-18       Impact factor: 3.714

8.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

9.  The role of monitoring vancomycin levels in patients with peritoneal dialysis-associated peritonitis.

Authors:  Sarah Stevenson; Wen Tang; Yeoungjee Cho; David W Mudge; Carmel M Hawley; Sunil V Badve; David W Johnson
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 10.  Peritoneal dialysis--current status and future challenges.

Authors:  Simon J Davies
Journal:  Nat Rev Nephrol       Date:  2013-05-21       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.